Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK3 | P52333 | 6/20 | 0.35 |
| ▸ | BTK | Q06187 | 4/20 | 0.35 |
| ▸ | HRH3 | Q9Y5N1 | 3/20 | 0.34 |
| ▸ | TEAD1 | P28347 | 2/20 | 0.33 |
| ▸ | KRAS | P01116 | 1/20 | 0.32 |
| ▸ | TET3 | O43151 | 2/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.31 |
| ▸ | FBXL19 | Q6PCT2 | 2/20 | 0.31 |
| ▸ | CXXC5 | Q7LFL8 | 2/20 | 0.31 |
| ▸ | TET1 | Q8NFU7 | 2/20 | 0.31 |
| ▸ | KDM2B | Q8NHM5 | 2/20 | 0.31 |
| ▸ | CXXC4 | Q9H2H0 | 2/20 | 0.31 |
| ▸ | KDM2A | Q9Y2K7 | 2/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26294933 | 0.91 | BTK (0.36) | JAK3BTKHRH3TEAD1KRAS | |
| SCHEMBL15474352 | 0.87 | BTK (0.41) | JAK3BTKTEAD1KRAS | |
| SCHEMBL21303477 | 0.83 | BTK (0.39) | BTKHRH3TET3KMT2AFBXL19 | |
| SCHEMBL16074977 | 0.83 | BTK (0.39) | BTKHRH3TET3KMT2AFBXL19 | |
| SCHEMBL16380183 | 0.81 | JAK3 (0.33) | JAK3BTKHRH3KRASTET3 | |
| SCHEMBL16375281 | 0.80 | CYP2D6 (0.41) | JAK3BTKHRH3KRAS | |
| SCHEMBL25009341 | 0.80 | SMN1; SMN2 (0.41) | HRH3 | |
| SCHEMBL15984372 | 0.78 | OPRL1 (0.36) | HRH3 | |
| SCHEMBL409261 | 0.78 | TEAD1 (0.45) | JAK3BTKTEAD1TET3KMT2A | |
| SCHEMBL16375283 | 0.77 | KMT2A (0.40) | JAK3BTKHRH3TEAD1TET3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9458162-B2 | Cyclic molecules as bruton's tyrosine kinase inhibitors | NANJING ALLGEN PHARMA CO. LTD. (CN) | 2016-10-04 | — | — | US | disclosed |
| US-20150011530-A1 | CYCLIC MOLECULES AS BRUTON'S TYROSINE KINASE INHIBITORS | GUANGDONG NEWOPP BIOPHARMACEUTICALS CO., LTD. (CN) | 2015-01-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150011530-A1 | CYCLIC MOLECULES AS BRUTON'S TYROSINE KINASE INHIBITORS | ABL1, BTK, PRKACA | JAK3 105/4885BTK 2/4885HRH3 3109/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.